Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2011-08-26 M&A Activity
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Medivirs dotterbolag, BioPhausia AB, har avyttrat sin generikaverksamhet
M&A Activity Classification · 99% confidence The document is a press release dated August 26, 2011, announcing that Medivir's subsidiary, BioPhausia AB, has sold its generics business (BMM Pharma AB) to Bluefish Pharmaceuticals AB. This announcement details a specific corporate transaction (divestiture/sale of a business unit) and provides context about the companies involved. This type of announcement, which details a significant corporate transaction like a sale or merger proposal, aligns best with the 'M&A Activity' category (TAR). It is not a standard regulatory filing like 10-K or IR, nor is it a general regulatory announcement (RNS) since it describes a specific, material event.
2011-08-26 Swedish
Medivir subsidiary BioPhausia AB sells generics business
Regulatory Filings Classification · 92% confidence The document is a press release dated August 26, 2011, announcing that Medivir's subsidiary, BioPhausia AB, sold its generics business to Bluefish Pharmaceuticals AB. This transaction involves a significant corporate action (sale of a business unit) that impacts the company's structure and operations, but it is not a standard periodic financial report (like 10-K or IR), a management change (MANG), or a dividend announcement (DIV). It is a specific corporate event announcement related to financing or corporate structure changes. Since it involves the sale of a business segment, it falls under the scope of major corporate transactions. While 'TAR' (M&A Activity) is for mergers/takeovers, this is a divestiture. Given the options, 'CAP' (Capital/Financing Update) is the closest fit as it relates to a change in the capital structure/asset base through a sale, or it could be classified as 'RNS' (Regulatory Filings) as a general corporate announcement. However, the sale of a major business unit is a significant corporate event often disclosed via press release, which aligns best with a general corporate announcement or a financing/asset change. Since it's a sale of a business segment, it's a significant corporate transaction. Given the specific definitions, 'CAP' covers financing activities, and a major asset sale is closely related to capital structure management. If a more specific M&A/Divestiture code existed, it would be used. Lacking that, and noting it's a material business transaction, I will classify it as a general regulatory filing/announcement, 'RNS', as it doesn't perfectly fit the other specific corporate action codes like CAP (which usually implies raising capital or debt changes). The document is short and is an announcement, not the full report.
2011-08-26 English
Number of shares and votes in Medivir
Share Issue/Capital Change Classification · 98% confidence The document is a short press release dated July 29, 2011, announcing a change in the total number of shares and votes due to the exercise of employee stock options. This directly relates to a change in the company's capital structure (share count). This aligns best with the 'Share Issue/Capital Change' definition (SHA), which covers changes in the number of shares outstanding. It is not a full financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Since it explicitly details the new total share count resulting from an issuance (exercise of options), SHA is the most precise fit.
2011-07-29 English
Antal aktier och röster i Medivir
Share Issue/Capital Change Classification · 99% confidence The document is a short press release dated July 29, 2011, titled "Antal aktier och röster i Medivir" (Number of shares and votes in Medivir). It explicitly states that the number of shares and votes has changed due to the exercise of employee stock options, providing the new total count as of the last trading day of the month. This type of announcement, detailing changes in the total number of outstanding shares and votes, is typically classified as a notification related to capital structure or share changes. Given the specific options, 'Share Issue/Capital Change' (SHA) is the most appropriate fit, as the change resulted from the exercise of options, increasing the share count. It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a Director's Dealing (DIRS) as it concerns the total company share count, not individual insider trades.
2011-07-29 Swedish
TMC435 has Received Fast Track Designation from the FDA and TMC435 will be studied in combination withPharmasset's PSI-7977 for HCV genotype-1
Regulatory Filings Classification · 95% confidence The document is a press release dated July 6, 2011, announcing that the investigational drug TMC435 received 'Fast Track' designation from the FDA for treating chronic hepatitis C. It details clinical trial plans, efficacy expectations, and provides background information on the drug and the disease. This type of announcement, focusing on regulatory milestones and clinical development updates, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a formal press release detailing significant operational/regulatory news rather than a full financial report (10-K, IR) or a transcript (CT), and it is not specifically about management changes (MANG), director dealings (DIRS), or capital structure (CAP), the most fitting category is Earnings Release (ER), as these often include key operational updates alongside financial highlights, or Regulatory Filing (RNS) as a general announcement. Given the focus on a major FDA designation and upcoming trial plans, it functions as a significant corporate update, often bundled with or released near earnings periods. However, since it is not explicitly labeled as an 'Earnings Release' but rather a 'Press Release' detailing a regulatory event, and it doesn't fit perfectly into the other specific categories, it leans towards a general regulatory announcement or an update that might accompany an ER. Since it is a standalone announcement of a significant event (FDA designation) and clinical progress, and not a comprehensive financial report, 'ER' is plausible if it's an interim update, but 'RNS' (Regulatory Filings) is the safest general category for non-standard, important announcements. Given the context of financial reporting databases, major regulatory milestones are often categorized under ER if they are time-sensitive operational news, or RNS if they are purely regulatory. I will classify it as ER because it contains forward-looking statements and operational progress updates typical of earnings-related communications, even if the primary topic is FDA designation.
2011-07-06 English
TMC435 har beviljats ”Fast Track” status av FDA och TMC435 kommer att ingå i en kombinationsstudie med Pharmassets PSI-7977 för HCV genotyp 1
Regulatory Filings Classification · 95% confidence The document is a press release dated July 6, 2011, announcing that the drug TMC435 has been granted 'Fast Track' status by the FDA for treating chronic Hepatitis C (HCV) genotype 1. It also announces plans for a combination study with Pharmasset's PSI-7977. This type of announcement, detailing significant regulatory milestones, clinical trial plans, and business developments, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a formal press release detailing key operational and regulatory news rather than a full financial report (10-K, IR) or a transcript (CT), and it is not specifically about management changes (MANG), director dealings (DIRS), or dividends (DIV), it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were less comprehensive. Given the detail on clinical trials and regulatory status, it functions as a major operational update, aligning closely with the scope of an ER, which typically covers period highlights and significant events. However, since it is not explicitly tied to a quarterly or annual financial reporting period summary (like 'Q2 results'), and it is a general press release about a specific development, the most appropriate general category for significant, non-standardized corporate news is often RNS, but ER is used for key operational/financial highlights. Given the focus on a major regulatory achievement (Fast Track) and upcoming clinical trials, it is a significant corporate announcement. If we must choose from the provided list, and it's not a formal financial report, it leans towards ER if it's near a reporting period, or RNS otherwise. Since it's a standalone press release detailing a major regulatory/clinical event, and not a standard financial report, RNS (Regulatory Filings/General Announcement) is a strong candidate, but ER often encompasses such major operational news. Let's re-evaluate: It's a 'Pressmeddelande' (Press Release). It details a regulatory win and future clinical plans. This is often bundled with ERs or treated as RNS. Since it's not a full financial report, and the content is highly specific operational news, I will classify it as an Earnings Release (ER) as these often contain the most significant operational news outside of mandatory filings, or RNS as a fallback. Given the context of financial reporting databases, major operational/regulatory news releases are often categorized as ER if they are timely, or RNS if they are purely regulatory/miscellaneous. I will select ER as it details significant progress on a key asset, which is typical for earnings commentary, even if not explicitly titled 'Earnings Release'. If RNS were chosen, it would be the fallback. I will stick with ER as the primary classification for significant operational news in a press release format.
2011-07-06 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.